Loading chat...
ME LD1847
Bill
Status
4/30/2025
Primary Sponsor
Anne Graham
Click for details
AI Summary
-
Establishes mandatory testing requirements for medical cannabis before sale, including testing for residual solvents, harmful chemicals, pesticides, molds, microbes, THC potency, and PFAS contamination
-
Creates a seed-to-sale tracking system for medical cannabis plants and products, allowing group tracking during cultivation and requiring detailed records from immature plant to retail sale or destruction
-
Sets THC limits for medical cannabis edibles at 10 mg per serving and 200 mg per package, with a 10% allowable variance rate for potency labeling
-
Dedicates at least 25% of adult use cannabis excise and sales tax revenue to public health and safety education programs covering both adult use and medical cannabis
-
Establishes a 13-member study group to examine youth cannabis consumption (under age 21), with a report due December 3, 2025 including recommendations on data collection and health effects
Legislative Description
An Act to Institute Testing and Tracking of Medical Use Cannabis and Cannabis Products Similar to Adult Use Cannabis and Cannabis Products, Dedicate a Portion of the Adult Use Cannabis Sales and Excise Tax to Medical Use Cannabis Programs and Create a Study Group
Cannabis
Last Action
Voted: Divided Report
2/12/2026